February 4, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice Concerning Non-Operating Income

SymBio Pharmaceuticals Limited ("the Company") announces the accrued non-operating income for the fourth quarter of the fiscal year ended December 31, 2020 (from October 1, 2020 to December 31, 2020) as follows.

1. Details of Non-Operating Income

   The Company recorded a foreign exchange gain of 14,360 thousand yen under non-operating income for the fourth quarter of the fiscal year ended December 31, 2020 (from October 1, 2020 to December 31, 2020) due to recent fluctuations changes in foreign exchange rates.
   In addition, with a foreign exchange loss of 55,648 thousand yen for the third quarter ended September 30, 2020, a net foreign exchange loss of 41,287 thousand yen was recorded as statements of operations for the fiscal year ended December 31, 2020.

2. Future Outlook

   Regarding the impact of the above non-operating income on the results of Company operations, please refer to the "Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)" announced today.

[Contact]
Investor Relations
Tel: +81(0)3 5472 1125